-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20

Benzinga·09/24/2026 15:47:23
Listen to the news
Citigroup analyst Yigal Nochomovitz upgrades Arcturus Therapeutics (NASDAQ:ARCT) from Neutral to Buy and raises the price target from $8 to $20.